We would love to hear your thoughts about our site and services, please take our survey here.
Doc
100% agreed.
Manifesto
I hope you’re well.
This is an interesting topic, although we are nowhere near EUA yet; there will be no application until much stronger data is achieved from another trial.
Anyone thinking anything other is delusional.
GLA LTHs
Jun-22 16:13:46 127.875 410,000 Buy* 524.29k O
Rather large.
As with any business failure, someone or somebody needs to be held to account.
Who is it?
Everyone who has shares will get the opportunity to vote on this.
I completed this today, via my share dealer.
Couple of NO’s; I’m sure you can guess which ones.
GLA
Dac
I emailed her months ago about the same point.
No response.
Sharedealer - are you ever wrong?
OB
Glad it’s worked out well for your family.
Regarding using SNG to aid recovery, I can’t see how anyone would have the right to administer an unapproved drug to anyone unless they were part of a specific trial.
ATB
That’s good news potentially, Dave.
ATB
Operation Warpspeed; hardly!
Seamless link; hardly.
Next?
PAHOO
Relax.
ATB
SD
Yes, I know an awful lot about SNG but didn’t want to appear to be cross ramping another share on this board, as that isn’t my intention.
ATB.
Let’s hope this flies up
Too many people appear to be very emotionally connected to this share; beware as it bit me on the behind with Synairgen.
Until this drug is proven to work, not proven to in this board by people that don’t know including me, keep your feet on the ground and remain cautious but positive.
Everything lined up perfectly for SNG, including excellent data from P2, great feedback from the company and the advertisement of jobs over the pond that we’re going for help with commercialisation of the drug.
Unfortunately, none of those jobs came to fruition as the trial failed to meet its endpoints. This came as a major shock to investors and talk of £20-£50 a share now seems like a joke.
GLA and to myself as I am hoping to recoup some of my paper losses in this share.
Freedom
TFG Asset Management UK LLP (formerly Polygon Global Partners LLP) who hold 52,401,577 shares.
DYOR
‘We now anticipate receiving the Phase 2 data from the ACTIV-2 team in the summer of 2022, which will be factored into the SNG001 clinical development plan to further build the case that SNG001 may have an important role in combatting COVID-19 and future emerging virus threats.’
Only thing that’s different is the slight change of timeline from first half of the year to summer 2022.
Everything else is as expected in a RNS for full year results.
We have received all of the other latest info recently.
Another wait for A2 data; it’s only been since Oct 21.
GLA
SD
You are the man - sorry for questioning your abilities.
‘A true legend in his own dinner hour.’
Shame you didn’t predict the RNS on that famous Monday in February.
I will try to look deeper, or maybe I’ll make 20 predictions and then when I get a couple correct, claim it was due to my superior techniques.
No need to reply SD; I get it.
ATB
Aether
I am extremely calm.
Just responding to the TR1 rubbish.
It’s not rocket science.
Only reason to be invested short term is for this Wednesday’s financials and for the A2 data, which should be here anytime in the next 1-5 weeks.
Once these have been delivered, depending on the strength of them, the plan for investors should be pretty clear.
My take is:
Strong feedback - either buy more and hold for the next year+ or sell on news and buy back in pre-further trial readout.
Mixed feedback - sell and invest elsewhere.
SD
My take on it is the buying volume is ridiculously low; there are NO big purchases!
Hence, why we went from 43p last Monday back to below 30p by the end of trading on Friday.
Maybe your theory is different?
It’s a very well known technique that has been used around the World very effectively, for centuries.
I’m getting the word ‘bull****’
Tommy
Thanks for sharing yet some more excellent posts.
Unlike many on here, I don’t get excited because RM had a little smile or because he looked like he knows it works - I think we’ve been there before and look what happened.
Just because we go on another trial, what will be different this time?
SOC hasn’t changed; we will however be targeting a specific group of hospitalised patients that have already shown statistical benefit from SNG001.
Time will tell, but until then I remain very cautious.
GLA
Manifesto
Agreed, although maybe RM is quite comfortable taking his hefty wage and just gearing up for the next round of research, rather than facing the pressures that commercialisation might bring?
The RNSs have been downplayed and poorly constructed imo. Is there ever a bullish remark made by him? Always ‘maybe’ or ‘if this happens’ or ‘if we can’.
If you get a response from Brooke, you’ve done better than me.
I’m in a pretty negative mindset of this company currently; the only problem is I’m stuck for the LT.
ATB.